Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib

INTRODUCTION: There are little data on the clinical activity of temsirolimus (TM) and everolimus (EV) when used as second-line therapy after sunitinib (SU) in patients with metastatic renal cell carcinoma (mRCC). METHODS: Patients with mRCC treated with EV or TM after SU were included in this retros...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Iacovelli, Roberto, Cartenì, Giacomo, Milella, Michele, Berardi, Rossana, Di Lorenzo, Giuseppe, Verzoni, Elena, Rizzo, Mimma, Santoni, Matteo, Procopio, Giuseppe
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Canadian Medical Association 2014
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3956829/
https://ncbi.nlm.nih.gov/pubmed/24678349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.1604
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak